Table 2 Clinical features and expression of NF-κB subunits in 533 patients with DLBCL
All patients, N (%) | p50+, N (%) | p52+, N (%) | p65+, N (%) | RELB+, N (%) | c-Rel+, N (%) | p50+/p65+, N (%) | p50+/c-Rel+, N (%) | p52+/RELB+, N (%) | |
|---|---|---|---|---|---|---|---|---|---|
Patients | 533 (100) | 150 (34) | 56 (12) | 92 (20) | 64 (14) | 103 (23) | 48 (11) | 49 (11) | 13 (3) |
Gender | |||||||||
Male | 306 (57) | 86 (57) | 29 (52) | 65 (71)* | 40 (63) | 54 (52) | 29 (60) | 26 (53) | 7 (54) |
Female | 227 (43) | 64 (43) | 27 (48) | 27 (29) | 24 (37) | 49 (48) | 19 (40) | 23 (47) | 6 (46) |
Age (years) | |||||||||
<60 | 230 (43) | 70 (47) | 33 (59)* | 45 (49) | 29 (45) | 37 (36) | 25 (52) | 16 (33) | 10 (77)* |
≥60 | 303 (57) | 80 (53) | 23 (41) | 47 (51) | 35 (55) | 66 (64) | 23 (48) | 33 (67) | 3 (23) |
B symptoms | |||||||||
Absent | 314 (67) | 88 (63) | 36 (72) | 56 (64) | 37 (71) | 57 (70) | 26 (55) | 30 (71) | 10 (83) |
Present | 154 (33) | 51 (37) | 14 (28) | 32 (36) | 15 (29) | 24 (30) | 21 (45) | 12 (29) | 2 (17) |
ECOG score | |||||||||
<2 | 388 (84) | 107 (83) | 40 (93) | 67 (85) | 39 (80) | 72 (89) | 36 (88) | 34 (83) | 8 (80) |
≥2 | 72 (84) | 22 (17) | 3 (7) | 12 (15) | 10 (20) | 9 (11) | 5 (12) | 7 (17) | 2 (20) |
Stage | |||||||||
I/II | 248 (48) | 65 (45) | 32 (60) | 44 (49) | 34 (56) | 54 (55) | 21 (44) | 25 (53) | 10 (83)* |
III/IV | 266 (52) | 80 (55) | 21 (40) | 46 (51) | 27 (44) | 44 (45) | 27 (56) | 22 (47) | 2 (17) |
Extranodal sites involved | |||||||||
<2 | 396 (78) | 110 (79) | 41 (84) | 69 (78) | 47 (78) | 59 (59) | 38 (81) | 38 (83) | 11 (92) |
≥2 | 114 (22) | 29 (21) | 8 (16) | 20 (22) | 13 (22) | 41 (41)* | 9 (19) | 8 (17) | 1 (8) |
LDH | |||||||||
Normal | 178 (37) | 47 (35) | 20 (41) | 30 (36) | 20 (38) | 27 (32) | 13 (30) | 12 (28) | 6 (55) |
Elevated | 304 (63) | 87 (65) | 29 (59) | 53 (64) | 33 (62) | 57 (68) | 31 (70) | 31 (72) | 5 (45) |
IPI | |||||||||
0–2 | 301 (58) | 82 (55) | 37 (66) | 55 (62) | 32 (52) | 59 (59) | 29 (63) | 25 (53) | 9 (69) |
3–5 | 221 (42) | 66 (45) | 19 (34) | 34 (38) | 30 (48) | 41 (41) | 17 (37) | 22 (47) | 4 (31) |
Tumor size (cm) | |||||||||
<6 | 270 (68) | 76 (67) | 25 (51) | 43 (64) | 26 (67) | 43 (62) | 22 (63) | 24 (69) | 7 (78) |
≥6 | 130 (32) | 37 (33) | 14 (49) | 24 (36) | 13 (33) | 26 (38) | 13 (37) | 11 (31) | 2 (22) |
Treatment response | |||||||||
CR/PR | 471 (88) | 132 (88) | 52 (93) | 79 (86) | 56 (88) | 92 (89) | 43 (90) | 41 (84) | 13 (100) |
No response | 62 (12) | 18 (12) | 4 (7) | 13 (14) | 8 (12) | 11 (11) | 5 (10) | 8 (16) | 0 (0) |
